Monthly Archives: July 2015

NQ Support Zone

As delighted as I am to see the NQ getting wrecked, I want to caution any bears out there (in case there are still any left besides me) that this drop is really just wiping the foam off the beer. We are falling back toward what is fairly strong support, pointed out below at the…

Illinois Tool Works Beats Q2 Earnings, Raises 2015 Outlook

Industrial tool maker Illinois Tool Works Inc. (ITW – Analyst Report) reported impressive results for second-quarter 2015. The company’s earnings came in at $1.30 per share, surpassing the Zacks Consensus Estimate of $1.28 as well as the year-ago tally of $1.21. Also, the bottom line scaled the higher end of Illinois Tool Works’ projected range of $1.22−$1.30 per share….

Interview Of Mark Papendieck, Of Orinoco Gold

TM Editors’ Note: This article discusses a microcap penny stock. Such stocks are very easily manipulated; do your own careful due diligence. The following interview of Managing Director Mark Papendieck of Orinoco Gold was conducted by Peter Epstein, CFA, MBA over the week ended July 20th. Orinoco Gold is an interesting gold junior with a soon-to-be-producing mine in the Brazilian State of Goias….

ECB And Twitter

The European Central Bank has been particularly busy. It is engaged in an asset buying program. Despite a European Court of Justice ruling highlighting the conflict of interest between its bank supervisory function and role as creditor, the ECB is still part of the Troika official creditors and participated in the marathon negotiating sessions over Greece.   The…

E

I am becoming a gold bug. While conspiracy theorists have been telling us, wrongly, for years that the price of gold is being manipulated, that doesn’t mean that there is no current fix going on now to shove down yellow metal price down. In fact, an unexpected player in the precious metal market almost certainly…

E

Biogen (BIIB) today reported new Phase 1B results for aducanumab in treating patients with Alzheimer’s. These results come from the trial known as the “PRIME” trial which split patients into two different dose groups. One group took different dosages of aducanumab, and the other group were given a placebo..  These results were presented today at…